You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

CLINICAL TRIALS PROFILE FOR VASOPRESSIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Vasopressin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004360 ↗ Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed Northwestern University 1995-09-01 OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004360 ↗ Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-09-01 OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed Northwestern University 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004364 ↗ Study of Novel Types of Familial Diabetes Insipidus Unknown status Northwestern University 1995-12-01 OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.
NCT00004364 ↗ Study of Novel Types of Familial Diabetes Insipidus Unknown status National Center for Research Resources (NCRR) 1995-12-01 OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vasopressin

Condition Name

Condition Name for Vasopressin
Intervention Trials
Septic Shock 24
Hyponatremia 13
Healthy 11
Congestive Heart Failure 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vasopressin
Intervention Trials
Shock 36
Shock, Septic 28
Heart Failure 22
Hemorrhage 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vasopressin

Trials by Country

Trials by Country for Vasopressin
Location Trials
United States 320
Canada 28
Germany 22
Italy 17
Greece 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vasopressin
Location Trials
California 21
New York 19
Texas 17
Ohio 16
Illinois 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vasopressin

Clinical Trial Phase

Clinical Trial Phase for Vasopressin
Clinical Trial Phase Trials
Phase 4 50
Phase 3 34
Phase 2/Phase 3 17
[disabled in preview] 77
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vasopressin
Clinical Trial Phase Trials
Completed 135
Recruiting 37
Unknown status 27
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vasopressin

Sponsor Name

Sponsor Name for Vasopressin
Sponsor Trials
Vantia Ltd 8
Otsuka Pharmaceutical Co., Ltd. 7
National Institute of Mental Health (NIMH) 7
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vasopressin
Sponsor Trials
Other 311
Industry 71
NIH 16
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Vasopressin: Clinical Trials, Market Analysis, and Projections

Introduction to Vasopressin

Vasopressin, also known as antidiuretic hormone (ADH), is a naturally occurring hormone secreted by the pituitary gland. It plays a crucial role in regulating water balance in the body and has various clinical applications, including the treatment of diabetes insipidus, certain post-surgical conditions, and severe cardiovascular disorders.

Clinical Trials Update

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest

Recent clinical trials have explored the efficacy of vasopressin in combination with other drugs for in-hospital cardiac arrest. The Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest (VAM-IHCA) trial, a multicenter, randomized, double-blinded, and placebo-controlled study, investigated the impact of a vasopressin-epinephrine-methylprednisolone combination on patient outcomes. The trial found a statistically significant increase in the return of spontaneous circulation (ROSC) for at least 20 minutes in the vasopressin and methylprednisolone group compared to the placebo group (42% vs. 33%)[1].

Vasopressin vs Norepinephrine in Septic Shock

The Vasopressin vs Norepinephrine as Initial Therapy in Septic Shock (VANISH) trial compared the effects of vasopressin and norepinephrine on kidney failure in patients with septic shock. This factorial, double-blind, randomized clinical trial conducted in the UK found that early vasopressin use, titrated up to 0.06 U/min, did not significantly differ from norepinephrine in terms of kidney failure-free days. However, it suggested that vasopressin might improve kidney function when used early in the treatment of septic shock, particularly when combined with corticosteroids[4].

Market Analysis

Current Market Size and Growth

The global vasopressin market has been growing steadily. In 2021, the market was valued at approximately $1,112.6 million and is projected to exhibit a Compound Annual Growth Rate (CAGR) of 14.7% from 2021 to 2028, reaching $2,912.0 million by 2028[2].

Market Drivers

Several factors are driving the growth of the vasopressin market:

  • Growing Prevalence of Diabetes Insipidus and Cardiovascular Diseases: The increasing incidence of diabetes insipidus and cardiovascular conditions such as cardiac arrest and septic shock is driving the demand for vasopressin therapies[3].
  • Enhanced Knowledge and Diagnosis: Earlier and more precise diagnosis of diseases treatable with vasopressin has increased the demand for the medication[3].
  • Technological Developments in Manufacturing: Improvements in biotechnology and pharmaceutical manufacturing processes have made vasopressin more widely available and affordable[3].
  • Research and Development Initiatives: Ongoing studies and clinical trials exploring new therapeutic uses for vasopressin are expanding its potential market[3].

Market Restraints

Despite the growth drivers, there are several factors that could hinder the market growth:

  • Complications from Vasopressin Use: Side effects such as asthma, epilepsy, heart disease, and heart failure can complicate the use of vasopressin, potentially limiting its adoption[2].

Key Players

The global vasopressin market is dominated by several major players, including Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, and others. These companies are involved in research, development, and distribution of vasopressin products[2].

Market Projections

Forecasted Growth

The vasopressin market is expected to continue its robust growth. By 2031, the market is projected to reach $2,656.9 million, growing at a CAGR of 13.8% from 2024 to 2031[3].

Regional Market Share

The market is geographically diverse, with significant shares in various regions. The increasing prevalence of conditions treatable with vasopressin and the development of healthcare infrastructure, particularly in emerging economies, are expected to drive regional growth[2].

Impact of COVID-19

The COVID-19 pandemic has had a mixed impact on the vasopressin market. While it has led to increased research and development in advanced vasopressin drugs due to the heightened risk of cardiac syndromes, it has also posed challenges in terms of supply chain disruptions and regulatory delays[2].

Hospital and Healthcare Infrastructure Development

The expansion of hospital and healthcare infrastructure, especially in emerging economies, is facilitating the wider availability and use of vasopressin. This development is a significant factor in the market's growth, as it increases access to vasopressin treatments for a broader patient population[3].

Regulatory Approvals

Recent regulatory approvals for new vasopressin formulations and drugs are also driving market growth. For instance, the U.S. FDA's priority review for Eagle Pharmaceuticals' abbreviated new drug application for vasopressin in 2021 highlights the ongoing regulatory support for vasopressin products[2].

Key Takeaways

  • Clinical Efficacy: Vasopressin has shown promising results in clinical trials, particularly in combination with other drugs for conditions like in-hospital cardiac arrest and septic shock.
  • Market Growth: The global vasopressin market is expected to grow significantly, driven by increasing prevalence of treatable conditions, technological advancements, and regulatory approvals.
  • Market Drivers: Growing prevalence of diabetes insipidus and cardiovascular diseases, enhanced diagnosis, and technological developments are key drivers.
  • Market Restraints: Complications from vasopressin use and regulatory challenges could hinder growth.
  • Regional Expansion: The market is expected to grow across various regions, driven by healthcare infrastructure development.

FAQs

What are the primary clinical applications of vasopressin?

Vasopressin is primarily used in the treatment of diabetes insipidus, certain post-surgical conditions, and severe cardiovascular disorders such as cardiac arrest and septic shock.

What are the key findings from the VAM-IHCA trial?

The VAM-IHCA trial found a statistically significant increase in the return of spontaneous circulation (ROSC) for at least 20 minutes in patients treated with a vasopressin-epinephrine-methylprednisolone combination compared to the placebo group.

How is the global vasopressin market expected to grow?

The global vasopressin market is projected to grow at a CAGR of 13.8% from 2024 to 2031, reaching $2,656.9 million by 2031.

What are the major drivers of the vasopressin market?

The major drivers include the growing prevalence of diabetes insipidus and cardiovascular diseases, enhanced knowledge and diagnosis, technological developments in manufacturing, and ongoing research and development initiatives.

Which companies are key players in the vasopressin market?

Key players include Par Pharmaceutical, Pfizer Inc., Novartis AG, Ferring Pharmaceuticals, Fresenius Kabi Canada, and others.

Sources

  1. Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest - SCCM Blog
  2. Vasopressin Market Size, Trends And Forecast To 2028 - Coherent Market Insights
  3. In-Depth Industry Outlook: Vasopressin Market Size & Forecast - Verified Market Research
  4. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients with Septic Shock - JAMA Network

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.